Xinru's view of Orlistat market analysis 01

With the pursuit of body shape and the understanding of secondary disease harm brought by obesity, Orlistat is becoming the drug of choice for weight loss and overweight people.

Orlistat market analysis

Orlistat inactivates lipase in the body by covalently binding to the active serine site of pancreatic lipase in the gastric and intestinal lumen. The body is unable to break down fats (mainly triglycerides) in food into absorbable free fatty acids and monoacylglycerols. So that people reduce calorie intake, control weight gain, achieve weight control, blood sugar, blood pressure, lipid regulation and other purposes.

Orlistat market analysis

The compound growth rate of global Orlistat API usage is expected to reach 22% in the next 5 years due to key factors such as large population of obesity patients and innovation of marketing model. Different regions of Orlistat’s global market have shown structural growth in recent years. On the one hand, the Orlistat API market is declining in developed markets; on the other hand, the main consumer market of Orlistat has shifted to emerging markets, and as the demand in these markets gradually opens up, the use of Orlistat has increased.

Orlistat market analysis: Global API production is mainly concentrated in China, India and Europe. On the one hand, India’s dependence on China has increased, on the other hand, China has increased the number of new API projects in the past two years, and the overall production capacity has increased significantly. China has become the largest producer of Orlistat APIs, which brings about changes in the global competition pattern of APIs.

Welcome to check our products! More info in Chinese.

Orlistat market analysis

Recent posts